Centessa Pharmaceuticals

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

Narcolepsy
#Centessa Pharmaceuticals #Eli Lilly #Mergers and acquisitions

Lilly acquires sleep-wake disorders specialist Centessa

Eli Lilly has announced a definitive agreement under which it will acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront and a potential equity value of $1.5 billion.  Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to… Read More

#Business & Investment #News

#Centessa Pharmaceuticals #Clinical trials #Narcolepsy #Neuroscience #Sleep disorders

Centessa initiates Phase II trial in patients with sleep/wake disorders 

Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.  ORX750 was designed using Nxera Pharma technology to directly… Read More

#News